Business

More Employers Expected to Turn to Biosimilars as Drug Costs Continue to Rise

October 22nd 2019

By Allison Inserro

A recent survey of employers regarding their concerns about growing healthcare costs reveals that some are looking to biosimilars as one method of controlling specialty drug spending.

List Prices for Medicare Part D Drugs Exceeded Inflation in 2016, 2017, Analysis Says

October 21st 2019

By Allison Inserro

While some data suggest that overall drug price increases may have moderated recently, prices for specific drugs continue to rise at rates above inflation.

Humana Alleges Price Fixing in Lawsuit Against Generic Drug Makers

October 21st 2019

By Kelly Davio

On Friday, Humana filed a lawsuit in the Eastern District of Pennsylvania, alleging that 37 defendants engaged in a “far-reaching conspiracy” to “blatantly fix the price” of generic drugs.

Eye on Pharma: Pfenex Reports Results of Human Factors Study for Follow-on Teriparatide

October 19th 2019

By The Center for Biosimilars Staff

Drug maker Pfenex announced this week that it has completed its comparative use human factors study for its follow-on teriparatide product, PF708, referencing the osteoporosis drug Forteo.

Pelosi Drug Pricing Bill Now Includes Amendment to Boost Biosimilars

October 18th 2019

By Allison Inserro

H.R. 3, The Lower Drug Costs Now Act, passed 2 committees in the House of Representatives Thursday, with a bipartisan amendment intended to boost uptake of biosimilars tucked inside.

Mundipharma Receives Positive CHMP Opinion for Pegfilgrastim Biosimilar

October 18th 2019

By Kelly Davio

Yesterday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of Mundipharma’s pegfilgrastim biosimilar.

Employer Groups Form Coalition on Drug Affordability, Support Policies Addressing Biosimilars

October 18th 2019

By Kelly Davio

A trio of employer groups has formed a new partnership to advocate for policies that address the problem of high—and growing—drug costs.

The Top 5 Biosimilars Articles for the Week of October 14, 2019

October 18th 2019

The Center for Biosimilars® recaps the top stories for the week of October 14, 2019.

NeuClone Begins Phase 1 Trial of Proposed Ustekinumab Biosimilar

October 17th 2019

By The Center for Biosimilars Staff

NeuClone said Thursday that it has begun dosing participants with its proposed ustekinumab biosimilar, referencing Stelara, in a phase 1 trial.

Belgian Competition Authority Investigating Practices Aimed at Blocking Biosimilars

October 17th 2019

By The Center for Biosimilars Staff

The Belgian Competition Authority, which contributes to implementing Belgium’s competition policy by addressing anticompetitive practices, announced that it is conducting inspections of some drug makers suspected of having implemented “restrictive practices aimed at limiting, delaying or even preventing the entry into the market or the expansion of biosimilar medicines competing with existing medicines."